Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6
CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning models can potentially predict interactions with CYP2B6; however, there is limited data with which to train these models in the public domai...
Uloženo v:
| Vydáno v: | Drug metabolism and disposition Ročník 53; číslo 10; s. 100160 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
01.10.2025
|
| Témata: | |
| ISSN: | 1521-009X, 1521-009X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning models can potentially predict interactions with CYP2B6; however, there is limited data with which to train these models in the public domain. We proposed enhancing the applicability domain and improving the predictive capability of our CYP2B6 inhibition model by selecting a small, diverse set of compounds to test in vitro and adding the results to our model training set. We used a distance-based approach to define the applicability domain of the model and then measured the chemical diversity by creating t-distributed stochastic neighbor embedding plots to represent the chemical space of our model. After comparing this chemical space with a 49-plate drug-repurposing library, we were able to identify a plate with the highest average minimum Euclidean distance from the model training set. We then performed in vitro testing of this plate for CYP2B6 inhibition activity at 10 μM and added this new data to our machine learning model. A one-class classification approach was used to evaluate the efficacy of our applicability domain-expansion technique. The results showed that this method did not appreciably increase the performance of the model or the applicability domain, but we did increase the diversity of the training set. Additionally, the in vitro experiments identified vilanterol and allylestrenol as inhibitors of CYP2B6 with IC
values in the sub to low micromolar range. SIGNIFICANCE STATEMENT: CYP2B6 inhibition can affect the metabolism of important drugs, like methadone and propofol, and result in variability that can lead to adverse events. Machine learning models can help uncover new molecules with inhibitory potential against CYP2B6, but only if predictions of these models are reliable. This study illustrates how the intentional expansion of a machine learning model's applicability domain is neither a simple nor straightforward task, but even a conservative effort can reveal new molecules with CYP2B6 inhibition activity. |
|---|---|
| AbstractList | CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning models can potentially predict interactions with CYP2B6; however, there is limited data with which to train these models in the public domain. We proposed enhancing the applicability domain and improving the predictive capability of our CYP2B6 inhibition model by selecting a small, diverse set of compounds to test in vitro and adding the results to our model training set. We used a distance-based approach to define the applicability domain of the model and then measured the chemical diversity by creating t-distributed stochastic neighbor embedding plots to represent the chemical space of our model. After comparing this chemical space with a 49-plate drug-repurposing library, we were able to identify a plate with the highest average minimum Euclidean distance from the model training set. We then performed in vitro testing of this plate for CYP2B6 inhibition activity at 10 μM and added this new data to our machine learning model. A one-class classification approach was used to evaluate the efficacy of our applicability domain-expansion technique. The results showed that this method did not appreciably increase the performance of the model or the applicability domain, but we did increase the diversity of the training set. Additionally, the in vitro experiments identified vilanterol and allylestrenol as inhibitors of CYP2B6 with IC50 values in the sub to low micromolar range. SIGNIFICANCE STATEMENT: CYP2B6 inhibition can affect the metabolism of important drugs, like methadone and propofol, and result in variability that can lead to adverse events. Machine learning models can help uncover new molecules with inhibitory potential against CYP2B6, but only if predictions of these models are reliable. This study illustrates how the intentional expansion of a machine learning model's applicability domain is neither a simple nor straightforward task, but even a conservative effort can reveal new molecules with CYP2B6 inhibition activity.CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning models can potentially predict interactions with CYP2B6; however, there is limited data with which to train these models in the public domain. We proposed enhancing the applicability domain and improving the predictive capability of our CYP2B6 inhibition model by selecting a small, diverse set of compounds to test in vitro and adding the results to our model training set. We used a distance-based approach to define the applicability domain of the model and then measured the chemical diversity by creating t-distributed stochastic neighbor embedding plots to represent the chemical space of our model. After comparing this chemical space with a 49-plate drug-repurposing library, we were able to identify a plate with the highest average minimum Euclidean distance from the model training set. We then performed in vitro testing of this plate for CYP2B6 inhibition activity at 10 μM and added this new data to our machine learning model. A one-class classification approach was used to evaluate the efficacy of our applicability domain-expansion technique. The results showed that this method did not appreciably increase the performance of the model or the applicability domain, but we did increase the diversity of the training set. Additionally, the in vitro experiments identified vilanterol and allylestrenol as inhibitors of CYP2B6 with IC50 values in the sub to low micromolar range. SIGNIFICANCE STATEMENT: CYP2B6 inhibition can affect the metabolism of important drugs, like methadone and propofol, and result in variability that can lead to adverse events. Machine learning models can help uncover new molecules with inhibitory potential against CYP2B6, but only if predictions of these models are reliable. This study illustrates how the intentional expansion of a machine learning model's applicability domain is neither a simple nor straightforward task, but even a conservative effort can reveal new molecules with CYP2B6 inhibition activity. CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning models can potentially predict interactions with CYP2B6; however, there is limited data with which to train these models in the public domain. We proposed enhancing the applicability domain and improving the predictive capability of our CYP2B6 inhibition model by selecting a small, diverse set of compounds to test in vitro and adding the results to our model training set. We used a distance-based approach to define the applicability domain of the model and then measured the chemical diversity by creating t-distributed stochastic neighbor embedding plots to represent the chemical space of our model. After comparing this chemical space with a 49-plate drug-repurposing library, we were able to identify a plate with the highest average minimum Euclidean distance from the model training set. We then performed in vitro testing of this plate for CYP2B6 inhibition activity at 10 μM and added this new data to our machine learning model. A one-class classification approach was used to evaluate the efficacy of our applicability domain-expansion technique. The results showed that this method did not appreciably increase the performance of the model or the applicability domain, but we did increase the diversity of the training set. Additionally, the in vitro experiments identified vilanterol and allylestrenol as inhibitors of CYP2B6 with IC values in the sub to low micromolar range. SIGNIFICANCE STATEMENT: CYP2B6 inhibition can affect the metabolism of important drugs, like methadone and propofol, and result in variability that can lead to adverse events. Machine learning models can help uncover new molecules with inhibitory potential against CYP2B6, but only if predictions of these models are reliable. This study illustrates how the intentional expansion of a machine learning model's applicability domain is neither a simple nor straightforward task, but even a conservative effort can reveal new molecules with CYP2B6 inhibition activity. |
| Author | Vignaux, Patricia A Harris, Joshua S Urbina, Fabio Ekins, Sean |
| Author_xml | – sequence: 1 givenname: Patricia A surname: Vignaux fullname: Vignaux, Patricia A organization: Collaborations Pharmaceuticals, Inc, Raleigh, North Carolina – sequence: 2 givenname: Joshua S surname: Harris fullname: Harris, Joshua S organization: Collaborations Pharmaceuticals, Inc, Raleigh, North Carolina – sequence: 3 givenname: Fabio surname: Urbina fullname: Urbina, Fabio organization: Collaborations Pharmaceuticals, Inc, Raleigh, North Carolina – sequence: 4 givenname: Sean surname: Ekins fullname: Ekins, Sean email: sean@collaborationspharma.com organization: Collaborations Pharmaceuticals, Inc, Raleigh, North Carolina. Electronic address: sean@collaborationspharma.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41061300$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLxDAUhYOMOA_9AW4kSzetSZp2muU4-IIBXSjoquRx62RIk9q06vx7C47g6p7v8HEWd44mPnhA6JySlBJaXO1S05iUEZaPPBbkCM1ozmhCiHid_MtTNI9xNyqcZ-IETTklBc0ImSG1altntVTW2X6PTWik9Ql8t9JHGzyO_WAsRFyHDjdSb60H7EB23vp33AQDLuIOPkE67OELW7-1yvahizjUeP32xK6LU3RcSxfh7HAX6OX25nl9n2we7x7Wq02iM7LsE1VIloEiIwgmSqlUbpRWinFleD1CaWohs9IInZdgSl4QnRcUNOeC6kyyBbr83W278DFA7KvGRg3OSQ9hiFXGckGWSyrIqF4c1EE1YKq2s43s9tXfX9gPL0toxQ |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.dmd.2025.100160 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1521-009X |
| ExternalDocumentID | 41061300 |
| Genre | Journal Article |
| GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AALRI AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 NPM O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YHG ZGI ZXP ~KM 7X8 |
| ID | FETCH-LOGICAL-c307t-b6a23eb03079298abb5dbcbb24bd4fb5d8df9a38d9c58ed8460c561ec4491c3a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001592286000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1521-009X |
| IngestDate | Thu Oct 09 19:00:39 EDT 2025 Sat Nov 01 14:17:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | t-SNE CYP2B6 Applicability domain Drug–drug interaction Machine learning |
| Language | English |
| License | Copyright © 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c307t-b6a23eb03079298abb5dbcbb24bd4fb5d8df9a38d9c58ed8460c561ec4491c3a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 41061300 |
| PQID | 3259077190 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3259077190 pubmed_primary_41061300 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-10-01 |
| PublicationDateYYYYMMDD | 2025-10-01 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Drug metabolism and disposition |
| PublicationTitleAlternate | Drug Metab Dispos |
| PublicationYear | 2025 |
| SSID | ssj0014439 |
| Score | 2.4798818 |
| Snippet | CYP2B6 is an important enzyme in the phase 1 metabolism of key pharmaceuticals, and inhibition of this enzyme can lead to adverse drug events. Machine learning... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 100160 |
| SubjectTerms | Cytochrome P-450 CYP2B6 - metabolism Humans Machine Learning |
| Title | Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41061300 https://www.proquest.com/docview/3259077190 |
| Volume | 53 |
| WOSCitedRecordID | wos001592286000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAMrDwfpSXjIQ61SKN7TwmVBAVA1QZCipT5FcgQ5NCCqJ_z7WTqgsDEkukDJYs--b6-N6TcxC6DGlgIqMEoSrkhGW-IhJuPyQ0KlTcQnZX73h-CIfDaDyOk6bgVjW0ykVOdIlal8rWyK8o4HQvDGHs9fSdWNco211tLDRWUYsClLGUrnC87CIw5pzE7BFFAEuMF11Nx-_SEysU6nOnQtQoVP6KMN1JM9j67xy30WaDMXG_DoodtGKKXdRJapHqeRePlv9cVV3cwclSvnq-h2S_7mk71uwc63Ii8oKYb0gbtrKGq5p5iAHt4omjYhrceE-8YmesU2GrCwUzAMiO8-Itl7n19MFlhm9fEv8m2EdPg7vR7T1pnBiIghwwIzIQPjXSJgSAU5GQkmuppPSZ1CyDl0hnsaCRjhWPjAZM4ykAZkYxFvcUFf4BWivKwhwhzKUOIqGN9rlhoheJQMVM8lgGkpuY0za6WKxtCpFu2xeiMOVnlS5Xt40O6w1Kp7UkR8rszZZ63vEfRp-gDbvvNSPvFLUy-M7NGVpXX7O8-jh3IQTPYfL4AzA00wQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Applicability+domain-expansion+studies+for+machine+learning+models+reveal+new+inhibitors+of+CYP2B6&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Vignaux%2C+Patricia+A&rft.au=Harris%2C+Joshua+S&rft.au=Urbina%2C+Fabio&rft.au=Ekins%2C+Sean&rft.date=2025-10-01&rft.eissn=1521-009X&rft.volume=53&rft.issue=10&rft.spage=100160&rft_id=info:doi/10.1016%2Fj.dmd.2025.100160&rft_id=info%3Apmid%2F41061300&rft_id=info%3Apmid%2F41061300&rft.externalDocID=41061300 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1521-009X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1521-009X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1521-009X&client=summon |